U.S. markets closed
  • S&P Futures

    4,363.00
    +2.00 (+0.05%)
     
  • Dow Futures

    34,246.00
    +14.00 (+0.04%)
     
  • Nasdaq Futures

    14,879.75
    +10.25 (+0.07%)
     
  • Russell 2000 Futures

    1,795.00
    +2.30 (+0.13%)
     
  • Crude Oil

    90.33
    +0.30 (+0.33%)
     
  • Gold

    1,943.60
    -2.00 (-0.10%)
     
  • Silver

    23.82
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0654
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     
  • Vix

    17.20
    -0.34 (-1.94%)
     
  • GBP/USD

    1.2245
    +0.0005 (+0.04%)
     
  • USD/JPY

    148.3860
    +0.0260 (+0.02%)
     
  • Bitcoin USD

    26,133.38
    -435.82 (-1.64%)
     
  • CMC Crypto 200

    558.41
    -9.63 (-1.70%)
     
  • FTSE 100

    7,683.91
    +5.29 (+0.07%)
     
  • Nikkei 225

    32,448.44
    +46.03 (+0.14%)
     

Exelixis achieves enrollment target for phase 3 trial of cabozantinib

Exelixis has reached the enrollment target of 960 patients for COMET-1, the company’s phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer. The primary endpoint of COMET-1 is overall survival, and Exelixis continues to expect top-line data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014.